Amyloid precursor protein
processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease.
Anandatheerthavarada, "Accumulation of amyloid precursor protein
in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction," The Journal of Neuroscience, vol.
HSV-1 also contribute to the formation of amyloid plaques and abnormally phosphorylated tau protein possibly by attenuating the processing of amyloid precursor protein
into toxic [beta]-amyloid peptide.
Three distinct point mutations have now been found in the amyloid precursor protein
gene at codon 717 that co-segregate with affected individuals in chromosome 21 linked families(9)(10)(11).
The study tracked brain PET imaging changes in 52 people: 27 from families with autosomal dominant Alzheimer's disease (ADAD) mutations, including presenilin 1 or amyloid precursor protein
genes, and 25 with sporadic Alzheimer's disease or mild cognitive impairment (MCI).
Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein
family members," Journal of Neuroscience, vol.
Instead the MGH team used a gel-based, three-dimensional culture system to grow human neural stem cells that carried variants in two genes -- the amyloid precursor protein
and presenilin 1 -- known to underlie early-onset familial Alzheimer's Disease (FAD).
secretase, a protease that cleaves amyloid precursor protein
(APP) within its transmembrane domain to produce amyloid E- (AE-).
Creating beta-amyloid requires the convergence of a protein called amyloid precursor protein
(APP) and an enzyme that cleaves APP into smaller toxic fragments called beta-secretase or BACE.
It has been shown that early-onset AD, accounting for about 5% of total AD cases, afflicts people at the age of 30 to 60, and is mainly caused by mutations of tree genes coding for the amyloid precursor protein
(APP) and presenilin 1/2 on chromosomes 21, 14, and 1, respectively.
have signed a collaboration and license agreement to develop a companion diagnostic to help screen patients for Merck's clinical development program for MK-8931, a novel oral beta amyloid precursor protein
site cleaving enzyme (BACE) inhibitor and Merck's lead candidate for Alzheimer's disease (AD).